) has been revised to $13.77 / share. This is an increase of 12.50% from the prior estimate of $12.24 dated November 7, 2025. The price target is an average of many targets provided by analysts. The ...
DURHAM, N.C., Feb. 28, 2023 /PRNewswire/ -- Real world evidence (RWE) leader, Target RWE, today shared new updates and insights from its longitudinal dermatology community of more than 4,000 patients, ...
Patient-Centric Data Capture Fuels Growth of Target RWE Longitudinal, Real-World Dermatology Studies
DURHAM, N.C., March 7, 2025 /PRNewswire/ -- Real-world evidence (RWE) leader, Target RWE, announced updates from its longitudinal dermatology study of more than 7,000 enrolled patients with two poster ...
Target PharmaSolutions has named Novartis as its first TARGET-DERM registry industry partner. Target PharmaSolutions has named Novartis as its first industry partner to provide multi-year support to ...
DURHAM, N.C., Jan. 11, 2023 /PRNewswire/ -- Target RWE, the leader and largest provider of real-world evidence (RWE) in non-cancer conditions, announced today the launch of 35 new observational ...
DURHAM, N.C., Feb. 27, 2019 /PRNewswire/ -- TARGET PharmaSolutions, Inc., a real-world clinical data solutions company, is pleased to announce that Novartis Pharma AG is the first industry partner to ...
DURHAM, N.C., March 8, 2024 /PRNewswire/ -- New patient-reported outcomes data presented at AAD 2024 from Target RWE's TARGET-DERM AA registry confirms the high unmet need and significant disease ...
The average one-year price target for Journey Medical (NasdaqCM:DERM) has been revised to $13.77 / share. This is an increase of 12.50% from the prior estimate of $12.24 dated November 7, 2025. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results